Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-08-22
1996-12-31
Killos, Paul J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
A01N 4346
Patent
active
055894755
ABSTRACT:
The use of a pharmaceutically acceptable cholinesterase inhibitor or a prodrug therefor for counteracting the sedative, hypnotic or respiratory depressive effects of benzodiazepines, substantially without interfering with the anxiolytic, antipsychotic, anticonvulsant, and muscle relaxant activity of benzodiazepines. When benzodiazepines are used for treatment of diseases where the sedative, hypnotic or respiratory depressive effects are undesirable, such as diseases selected from the group consisting of anxiety, anxiety neurosis, anxiety reactions, panic reactions, schizophrenia, affective or schizoaffective type schizophrenia, borderline psychosis, agitating endogene depressions, hyperactivity in children, and muscle spasms, the cholinesterase inhibitor of the present invention is particularly effective. The invention also is directed to use a pharmaceutically acceptable cholinesterase inhibitor or a prodrug therefor for the treatment of schizophrenia, in particular affective or schizoaffective type schizophrenia. The acetyl cholinesterase is preferably one that acts substantially selectively at nicotinic receptor sites, and which has selectively for acetyl cholinesterase opposed to butyryl cholinesterase, e.g., galanthamine or a galanthamine derivative.
REFERENCES:
CA 112: 48617 1989.
Medline 85: 195065 1985.
CA 110: 51228 1988.
Chemical Abstracts 92:121768q (1980).
Chemical Abstracts 101:16845u (1984).
Foster, et al. "Physostigimine Reversal Of Diazepam-Induced Depression," Anethesia and Analgasia 56(3): 348-352 (May-Jun. 1977).
Vateshsky, et al. "Mechanism Of Antagonism By Physostigimine Of Acute Flunitrazepam Intoxication," Anesthesiology 64(2): 248-252 (1986).
Blitt, et al. "Reversal Of Lorzaepam Delirium By Physostigmine," Anesthesia and Analgesia 54(5): 607-608 (Sep. Oct. 1975).
Lauven, et al. "Flumazenil (Ro 15-1788) and Physostigmine," Resuscitation 16/suppl., 542-548 (1988).
Hoffman, et al. "Cerebrovascular and Cerebral Metabolic Effects of Physostigmine, Midazolam, and a Benzodiazepine Antagonist," Anesthesia and Analgesia 65(6): 639-644 (Jun. 1986).
Pandit, et al. "Physostigmine Fails To Reverse Clinical Psychomotor, or EEG Effects Of Lorazepam," Anesthesia and Analgesia 62(7): 79-685 (Jul. 1983).
Deutsch, et al. "Acetylcholinesterase Activity in CSF in Schizophrenia, Depression, Alzheimer's Disease, and Normals," Biological Psychiatry 18(12): 1363-13763 (Dec. 1983).
LandOfFree
Benzodiazepine treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzodiazepine treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzodiazepine treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1142261